Selective Macrocyclic WEE1 Kinase Inhibitors with Strong Efficacy against Patient-Derived Colorectal Cancer Organoids

Authors:

Abstract
Macrocyclization can enhance the selectivity of acyclic compounds toward structurally similar biological targets such as kinases. WEE1 regulates cellular homeostasis and is a promising target in oncology. The clinical candidate AZD1775 (1) failed to progress past Phase II trials because of patient tolerability issues, likely due to off-target inhibition of polo-like kinase 1 (PLK1). Herein, a computer-aided drug design approach was conducted to develop a macrocycle based on the 1-WEE1 X-ray cocrystal structure. Significantly enhanced WEE1 inhibitory selectivity over PLK1 was determined for leading macrocycle 2, which also demonstrated broader kinome-wide selectivity. Patient-derived organoids from colorectal cancer (CRC) peritoneal and liver metastases, treated with 2, demonstrated comparably strong or enhanced anticancer efficacy compared to that of 1. Against patient-matched normal colon vs primary CRC organoids, 2 potently and selectively treated CRC, as well as enhanced DNA damage compared to 1. Finally, the X-ray cocrystal structure of 2 bound to WEE1 validated its computationally predicted bioactive binding mode.
Funding Information
  • National Health and Medical Research Council
  • South Australian Health and Medical Research Institute
  • Therapeutic Innovation Australia (TIA), Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) program
  • Australian Government Research Training Program Scholarship
  • The Gastroenterological Society of Australia Bushell Research Fellowship
  • Faculty of Health Science at the University of Adelaide
  • Monash Graduate Excellence Scholarship provided by Monash University

This publication has 85 references indexed in Scilit: